Clinical Kidney Journal最新文献

Background: Patients with chronic kidney disease (CKD) are frequently hospitalized for heart failure. Sodium-glucose co-transporter 2 (SGLT2)-inhibitors improve cardiorenal outcomes in CKD and heart failure, at least in estimated glomerular filtration rate (eGFR) ranges 20-60 ml/min/1.73 m², possibly through direct cardiac effects. In the cardiac imaging sub-studies of the Renal Lifecycle Trial, we aim to establish the effects of SGLT2-inhibition on cardiac structure and function in patients with advanced CKD, kidney failure and in kidney transplant recipients.

Methods: In the Renal Lifecycle Trial, patients with advanced CKD (eGFR ≤25 ml/min/1.73 m²), those treated with hemodialysis or peritoneal dialysis (PD) or kidney transplant recipients (eGFR ≤45 ml/min/1.73 m²), are randomized to receive either dapagliflozin or placebo. The echocardiography sub-study (acronym: STOP-HF-in-PD) will enroll 100 PD-treated patients, who undergo echocardiography at baseline, and at 6 and 12 months post-randomization. In the cardiac magnetic resonance imaging (MRI) sub-study, 250 Renal Lifecycle Trial participants across all three groups (i.e. advanced CKD, dialysis, kidney transplant recipients), including a subset of STOP-HF-in-PD participants, will undergo cardiac MRI at baseline, and at 12 months post-randomization. The primary endpoint of STOP-HF-in-PD is the difference in left ventricular global longitudinal strain, a measure of cardiac function, after 6-months of dapagliflozin compared to placebo. For the cardiac MRI sub-study, the primary endpoint is the difference of indexed left ventricular mass after 12 months of dapagliflozin compared to placebo.

Conclusions: The Renal Lifecycle Trial cardiac imaging sub-studies will generate novel data on the effects of SGLT2-inhibition on cardiac structure and function in a population with advanced CKD, in whom SGLT2-inhibitor induced cardiovascular protection remains to be established.

Clinical trial registration: The Renal Lifecycle Trial and its sub-studies are registered at ClinicalTrials.gov under registration number NCT05374291.

Mucosal-associated invariant T (MAIT) cells are a distinct subset of innate-like lymphocytes that bridge microbial homeostasis and tissue immunity. These evolutionarily conserved cells are activated via the recognition of microbial metabolites presented by the MR1 molecule and establish stable residency in the kidney, where they profoundly influence local immune-metabolic processes. There is growing interest in the robust regulatory capacities of MAIT cells in renal physiology and pathology. This review systematically delineates their paradoxical roles in kidney diseases. Under specific conditions, they exert protective functions by suppressing inflammation and maintaining tissue homeostasis. Conversely, in distinct microenvironments, they adopt a pro-inflammatory phenotype, exacerbating pathological progression through the release of inflammatory cytokines and cytotoxic effector functions. The gut-kidney axis serves as a critical regulatory hub, wherein dysbiosis-derived signals can significantly amplify the renal impact of MAIT cells. Focusing on clinical translation, we provide an in-depth exploration of innovative strategies targeting MAIT cells, including adoptive cell therapy, receptor-targeting agents, and microbiome reconstruction. These approaches position MAIT cells as promising therapeutic targets for a new generation of immune-mediated kidney diseases.

Tenapanor, a selective inhibitor of the sodium/hydrogen exchanger isoform 3 (NHE3), was initially developed for the treatment of irritable bowel syndrome with constipation. Subsequent preclinical and clinical studies revealed its ability to reduce gastrointestinal phosphate absorption, leading to effective serum phosphate control with minimal pill burden in patients with kidney failure undergoing dialysis therapy. However, the precise mechanisms underlying NHE3 inhibition, its impact on phosphate handling and the primary site of action within the gastrointestinal tract remain incompletely understood. This review explores the hypothesis that tenapanor-induced NHE3 inhibition elevates the luminal pH via enhanced bicarbonate secretion in the colon, thereby altering phosphate speciation. Phosphate exists in the body as monovalent (H₂PO₄⁻) and divalent (HPO₄²⁻) anions, with the latter predominating under alkaline conditions. Although divalent anions are theoretically more prone to be absorbed from the gut lumen via the paracellular transport route because of the lumen-negative transepithelial potential, on the contrary recent studies have provided evidence that monovalent species are transported more efficiently and that paracellular phosphate permeability is suppressed at high luminal pH. We now propose that the net negative electrostatic environment within the paracellular pore pathway of tight junctions may selectively hinder divalent phosphate transport. This hypothesis aligns with prior findings that tenapanor does not alter the expression of tight junction proteins, suggesting a physicochemical rather than a structural basis for reduced permeability. Further investigations are warranted to determine whether the electrostatic properties of the paracellular pathway contribute to the phosphate-lowering effect of tenapanor.

Background: Sepsis-associated acute kidney injury (S-AKI) represents a critical complication with high mortality rates in intensive care units. Current risk stratification tools lack precision and interpretability for clinical decision-making. This study aimed to develop and validate interpretable machine learning models for predicting hospital mortality in S-AKI patients.

Methods: This retrospective cohort study utilized five international critical care databases: Medical Information Mart for Intensive Care (MIMIC)-IV (n = 12 966), MIMIC-III-CareVue (n = 2209), eICU (n = 8210), Northwestern University Intensive Care Unit (NWICU) (n = 2207) and Salzburg Intensive Care database (SICdb) (n = 1893). Adult patients with S-AKI meeting sepsis-3.0 and acute kidney injury criteria were included. Feature selection used the Boruta algorithm on MIMIC-IV, MIMIC-III and eICU databases. Eleven machine learning algorithms were trained using MIMIC-IV data with external validation on all other datasets. Performance was evaluated using receiver operating characteristic (ROC) curve analysis, calibration plots and decision curve analysis. SHapley Additive exPlanations (SHAP) analysis provided model interpretability.

Results: Among 27 485 S-AKI patients, hospital mortality was 27.5%. Boruta identified 21 consensus features including severity scores [Simplified Acute Physiology Score II (SAPS II), Sequential Organ Failure Assessment (SOFA), OASIS], vital signs and laboratory parameters. Gradient Boosting Machine emerged as optimal with area under the curve (AUC) values of 0.770 (training), 0.731 (internal validation) and 0.732-0.778 across four external validation cohorts. The model demonstrated excellent calibration and minimal overfitting (3.9% AUC difference). Decision curve analysis revealed superior clinical utility across probability thresholds of 4%-82%. SHAP analysis identified SAPS II as the most important predictor, with scores >60 and SOFA >15 associated with substantially increased mortality risk. Complete case analysis confirmed model robustness (AUC 0.766-0.847).

Conclusions: The interpretable machine learning model demonstrated excellent performance and robust generalizability for S-AKI mortality prediction across five international databases. SHAP analysis provided clinically meaningful insights supporting personalized risk stratification and evidence-based clinical decision-making.

Background: Among patients receiving immune checkpoint inhibitor (ICI) therapy, the most common renal immune-related adverse event is interstitial nephritis, which is caused by severe T-cell infiltration and is typically responsive to steroids; although rarer, autoimmune induction in the kidney has also been reported. There is a paucity of data regarding ICI-induced autoimmune disease in the kidney and the challenges associated with continuing ICI therapy. Here, we present a single center case series of ICI-induced glomerulonephritis with data on treatment rechallenge.

Methods: We retrospectively reviewed 241 patients who underwent kidney biopsies at our institution between 2015 and 2024 and identified those who had non-vasculitis-associated glomerulonephritis after ICI therapy. Demographics, renal toxicity, renal response, disease response, and overall survival data were extracted from the patients' medical records. We defined renal response based on creatinine and proteinuria using KDIGO guidelines. We also performed a literature review to identify published cases of ICI-induced glomerulonephritis. Differences between treatment groups were assessed with a two-sided, two-sample t-test and Wilcoxon test or with a chi-square test, as appropriate.

Results: Among 241 kidney biopsies we identified 16 patients with non-vasculitic GN, eight received rituximab with or without corticosteroids, and eight received corticosteroids only, for ICI-induced glomerulonephritis. The median proteinuria grades in the rituximab and corticosteroid groups were 3 and 1, respectively. The median corticosteroid treatment duration in the rituximab group (2.5 weeks) was shorter than that in the corticosteroid group (8 weeks). In the rituximab group, 75% of patients underwent ICI rechallenge and had no proteinuria relapse. Patients who received rituximab had better change in proteinuria response than those who received corticosteroids (P value = .029). Among the 42 patients we identified from the literature review, renal response did not differ significantly between the 10 who received rituximab and the 32 who did not.

Conclusion: Use of Rituximab in treatment of ICI-induced GN is an attractive option to reduce steroids exposure allowing continued ICI treatment for overall improved renal outcome. Clinical trials to evaluate these findings are needed.

Background: Renal thrombotic microangiopathy (TMA) remains a challenge for lupus nephritis (LN) patients. The purpose of this study was to determine the prognostic significance of renal TMA in patients with LN.

Methods: Patients were recruited from the LN database (http://ln.medidata.cn) of the First Affiliated Hospital of Sun Yat-Sen University between 2001 and 2023. To assess the association between renal TMA and kidney recovery outcomes, propensity score matching (PSM), and Cox proportional hazards regression analysis were used.

Results: 5.17% LN patients had kidney biopsies showing TMA. After PSM, patients with renal TMA exhibited lower scores on the Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) and the Activity Index (AI) scores in renal biopsies. Renal TMA was independently associated with deteriorated renal function recovery compared with non-renal TMA [hazard ratio (HR) 0.62; 95% confidence interval (CI) 0.42-0.94, P = .022). This association remained significant after PSM (HR: 0.50; 95% CI: 0.31-0.82, P = .004). Additionally, renal TMA was independently associated with higher risk of renal replacement therapy (RRT) (HR: 6.90; 95% CI: 3.57-13.30, P < .001) in LN patients. The proportion of glomerulosclerosis is a predictive factor for renal function recovery in LN patients with renal TMA (HR: 0.62; 95% CI: 0.40-0.95, P = .027).

Conclusions: Renal TMA is strongly associated with poorer renal function recovery in LN patients. Furthermore, a higher degree of glomerulosclerosis is a significant risk factor for impaired recovery in these patients.

Immunoglobulin A nephropathy (IgAN) remains the most common primary glomerulonephritis globally. Advances in mucosal immunology have illuminated the role of dysregulated B cell activity, galactose-deficient IgA1 (Gd-IgA1) and Gd-IgA1-specific antibody formation in driving disease pathogenesis. Therapeutic targeting of the mucosal immune system and, more specifically, B cell survival and differentiation pathways have entered late-stage development, offering a mechanistically guided approach to disease modification. Targeting of the gut-associated lymphoid tissue of the terminal ileum, B cell activating factor and/or a proliferation-inducing ligand antagonists and CD38-targeted agents have all demonstrated efficacy in reducing proteinuria and preserving kidney function. Emerging cellular and bispecific platforms, although early in development, raise the prospect of deeper immunologic remodelling. Precision tools such as Gd-IgA1 quantification, single-cell transcriptomics and pharmacogenomics are being explored to optimise treatment selection and duration. As real-world data and long-term safety outcomes accumulate, B cell-directed therapies are likely to become a commonly used treatment option in IgAN.

Background: Over the last 30 years, with increasing comorbidity and frailty among people with end-stage kidney disease, there is recognition that dialysis may carry little benefit in some patient groups. We examined the utility of the electronic frailty index (eFI), modelling the survival time of patients starting dialysis at a single renal unit in northern England, hypothesising this would give useful prognostic survival information.

Methods: Two datasets describing the same population of patients receiving dialysis over a 226-month period (2000-2019) at a single dialysis unit were used (n = 599 and 553 participants). One dataset was derived from primary care (linked to UK Renal Registry submissions) and the other from the UK Renal Registry (linked with primary care data to facilitate eFI calculation). Retrospective survival analysis was undertaken with hazard ratios for the impact of eFI and other covariates on survival.

Results: The frailty score at dialysis start has a strong effect on subsequent survival time using either the primary care-derived or UK Renal Registry dataset, but there were differences in overall survival and the relation between eFI score and survival between datasets.

Conclusions: This represents the first study of eFI utility within tertiary renal care, demonstrating a strong association between frailty measured by eFI and survival time for patients on dialysis. However, significant differences between primary care-derived and UK Renal Registry-derived survival at different frailty scores were demonstrated. These differences indicate a need for greater understanding and analysis of large datasets before using them to discuss patient treatment choices, service planning and delivery.